Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  American Journal of Cardiology

• Publication date

  2003-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.AMJCARD.2003.08.048PMID 14675576
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

  2003cited by this paper
• Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus.

  2003cited by this paper
• Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.

  2003cited by this paper
• Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial

  2003cited by this paper
• Ezetimibe: efficacy and safety in clinical trials

  2002cited by this paper
• Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

  2002cited by this paper
• Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans

  2002cited by this paper
• Simvastatin Lowers C-Reactive Protein Within 14 Days: An Effect Independent of Low-Density Lipoprotein Cholesterol Reduction

  2002cited by this paper
• Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.

  2002cited by this paper
• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

  2002cited by this paper
• Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia.

  2002cited by this paper
• Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.

  2002cited by this paper
• Energy Restriction and Weight Loss on Very-Low-Fat Diets Reduce C-Reactive Protein Concentrations in Obese, Healthy Women

  2001cited by this paper
• Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

  2001cited by this paper
• Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

  2001cited by this paper
• Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia

  2001cited by this paper
• Clinical efficacy of an automated high-sensitivity C-reactive protein assay.

  1999cited by this paper
• Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

  1998cited by this paper
• Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment.

  1996cited by this paper

• Targeting Atherosclerosis: Cholesterol-Lowering Therapies with a New Immunometabolic Dress for an Old Disease

  2025cites this paper
• Comparison of ezetimibe and atorvastatin versus atorvastatin alone on short-term major adverse cardiac events after percutaneous coronary intervention, a double-blind placebo-controlled randomized clinical trial

  2025cites this paper
• Pharmacokinetics and Bioequivalence of Fixed‐Dose Combination of Simvastatin and Ezetimibe Tablets: A Randomized, Crossover, Open‐Label Study in Healthy Volunteers

  2024cites this paper
• Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review

  2023cites this paper
• Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review

  2023cites this paper
• The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials

  2022cites this paper
• Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.

  2022cites this paper
• Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols

  2020cites this paper
• Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials

  2019influential citation
• EFFECTIVENESS OF EZETIMIBE IN ROUTINE CLINICAL PRACTICE

  2018cites this paper
• Protective Effects of Simvastatin Against Alendronate-Induced Gastric Mucosal Injury in Rats

  2016cites this paper
• Biochemical Efficacy and Clinical Benefit of Dual Inhibition of Cholesterol Using Ezetimibe and Simvastatin

  2016cites this paper
• The effect of ezetimibe monotheraphy on mean platelet volume in patients with hyperlipidaemia: a retrospective study of 45 patients.

  2016cites this paper
• Effects of Simvastatin, Ezetimibe, and Their Combination on Histopathologic Alterations Caused by Adjuvant-Induced Arthritis

  2014cites this paper
• Metalloproteinases and metalloproteinase inhibitors in age-related diseases.

  2014cites this paper
• Influence of Previous Statin Therapy on Cholesterol-Lowering Effect of Ezetimibe

  2014cites this paper
• Assessment of Low-Density Lipoprotein Targets

  2013cites this paper
• Problems and Possible Solutions for Therapy with Statins

  2013cites this paper
• Increasing Doses of Simvastatin Versus Combined Ezetimibe/Simvastatin

  2013cites this paper
• Biomarkers in Essential Hypertension

  2013cites this paper
• Biomarkers in Hyperlipidemia

  2013cites this paper
• Eficacia bioquímica y beneficio clínico de la doble inhibición con ezetimiba y simvastatina

  2012cites this paper
• Effects of simvastatin, atorvastatin, ezetimibe, and ezetimibe + simvastatin combination on the inflammatory process and on the liver metabolic changes of arthritic rats

  2012cites this paper
• Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin.

  2012influential citation
• A Case Study of Single‐Pill Combination Therapy: The Ezetimibe/Simvastatin Combination for Treatment of Hyperlipidemia

  2012cites this paper
• Inflammatory markers in hyperlipidemia: from experimental models to clinical practice.

  2011cites this paper
• Effects of Ezetimibe Added to Ongoing Statin Therapy on C-Reactive Protein Levels in Hypercholesterolemic Patients

  2011cites this paper
• Preparation, characterization of hydrophilic and hydrophobic drug in combine loaded chitosan/cyclodextrin nanoparticles and in vitro release study.

  2011cites this paper
• Treatment of dyslipidemia in the elderly

  2011cites this paper
• Intestinal sterol transporters and cholesterol absorption inhibition

  2011cites this paper
• Clinical perspective: have the results of recent clinical trials of lipid-lowering therapies influenced the way we should practice? A Latin American perspective of current issues in clinical lipidology.

  2011cites this paper
• Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment.

  2011cites this paper
• The IMPROVE-IT trial: current status and potential clinical implications of ezetimibe

  2011cites this paper
• A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms.

  2011cites this paper
• Women and Cardiovascular Disease—Prevention of Heart Disease

  2011cites this paper
• Topical anti‐inflammatory effect of hypocholesterolaemic drugs

  2011cites this paper
• Ezetimibe and reactive oxygen species.

  2011cites this paper
• ARTICLE ORIGINAL / ORIGINAL ARTICLE BENEFIT AND TOLERABILITY OF THE COADMINISTRATION OF EZETIMIBE AND ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS

  2011cites this paper
• Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes

  2011cites this paper
• Potential therapeutic uses for ezetimibe beyond lowering LDL‐c to decrease cardiovascular events

  2010cites this paper
• Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects

  2010cites this paper
• Effects of Ezetimibe Add-on to Statin Therapy on Adipokine Production in Patients With Metabolic Syndrome and Stable Vascular Disease

  2010cites this paper
• Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither

  2010cites this paper
• [Problems with statins and the marketing of these medications].

  2010cites this paper
• Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.

  2010cites this paper
• Update on the efficacy and safety of combination ezetimibe plus statin therapy

  2010cites this paper
• Перспективы применения эзетимиба в кардиологической практике

  2010cites this paper
• Estudo da atividade inflamatória e plaquetária em pacientes com doença arterial coronária estável, submetidos a tratamento com duas estratégias hipolipemiantes intensivas: sinvastatina 80 mg e ezetimiba 10 mg/sinvastatina 20 mg

  2010cites this paper
• Pleiotropic Effects With Equivalent Low-density Lipoprotein Cholesterol Reduction: Comparative Study Between Simvastatin and Simvastatin/Ezetimibe Coadministration

  2010cites this paper
• Statin and ezetimibe combination therapy in cardiovascular disease

  2009cites this paper
• Impact of ezetimibe on atherosclerosis: is the jury still out?

  2009cites this paper
• The impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemia.

  2009cites this paper
• A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol in metabolic syndrome patients.

  2009cites this paper
• Premature release of data from clinical trials of ezetimibe.

  2009cites this paper
• Hyperlipidemia in older adults.

  2009cites this paper
• Lipid-lowering drugs acting at the level of the gastrointestinal tract.

  2009cites this paper
• Zielwerterreichung unter lipidsenkender Therapie mit Ezetimib/Simvastatin bei Patienten mit Atherosklerose und/oder Diabetes mellitus – eine österreichische Anwendungsbeobachtung

  2009cites this paper
• [Achievement of blood lipid target levels with Ezetimibe/Simvastatin in patients with atherosclerosis and/or diabetes mellitus--an Austrian observational study].

  2009cites this paper
• Endothelial dysfunction in patients with glucose abnormalities and coronary artery disease

  2009cites this paper
• Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation

  2009cites this paper
• The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients

  2009cites this paper
• Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease.

  2008cites this paper
• ENHANCE – After the Dust Has Settled, Is Low-density Lipoprotein Cholesterol Lowering What It Once Was?

  2008cites this paper
• Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.

  2008cites this paper
• Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study

  2008cites this paper
• Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.

  2008cites this paper
• The Pleiotropic Effect is Essential for the Benefit of Treatment with Statins Agonist

  2008cites this paper
• Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin.

  2008cites this paper
• Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study.

  2008cites this paper
• The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview.

  2008cites this paper
• Is There a Problem With Ezetimibe or Just ENHANCEd Hype?

  2008cites this paper
• Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein.

  2008cites this paper
• Pretreatment With High-Dose Statin, But Not Low-Dose Statin, Ezetimibe, or the Combination of Low-Dose Statin and Ezetimibe, Limits Infarct Size in the Rat

  2008cites this paper
• Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis.

  2008cites this paper
• Ezetimibe: cholesterol lowering and beyond

  2008cites this paper
• Phytosterolemia: Synthesis, Absorption, Trafficking, and Excretion of Cholesterol and Noncholesterol Sterols

  2007cites this paper
• Safety considerations with fibrate therapy.

  2007cites this paper
• Lipid management and peripheral arterial disease.

  2007cites this paper
• Cost–effectiveness analysis of genetic screening for the Taq1B polymorphism in the secondary prevention of coronary heart disease

  2007cites this paper
• Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.

  2007cites this paper
• The Effects of High Dose Pravastatin and Low Dose Pravastatin and Ezetimibe Combination Therapy on Lipid, Glucose Metabolism and Inflammation

  2007cites this paper
• Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus *

  2007cites this paper
• Expert commentary: gastrointestinally active lipid-lowering drug safety.

  2007cites this paper
• Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction

  2007cites this paper
• EL SÍNDROME METABÓLICO EN LA CLÍNICA ACTUAL

  2007cites this paper
• Ezetimibe : cholesterol lowering & beyond

  2007cites this paper
• Statins and C‐Reactive Protein Levels

  2007cites this paper
• Lipids and Peripheral Arterial Disease

  2007cites this paper
• Co‐administration of ezetimibe and simvastatin in acute myocardial infarction

  2007cites this paper
• Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy

  2007cites this paper
• Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis.

  2007cites this paper
• Statin therapy-evidence beyond lipid lowering contributing to plaque stability.

  2006cites this paper
• Pathophysiology, diagnosis, and management of dyslipidemia.

  2006cites this paper
• Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview

  2006cites this paper
• Ezetimib - první zástupce selektivních inhibitorů cholesterolové absorpce

  2006cites this paper
• Beneficios de la terapia combinada en la hiperlipemia

  2006cites this paper
• Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia.

  2006cites this paper
• [Intensive cholesterol lowering therapy to reduce cardiovascular risk].

  2006cites this paper
• Statin therapy for native and peri-interventional coronary heart disease.

  2006cites this paper
• Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction

  2006cites this paper